RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation

Abstract Multiple myeloma (MM) is still considered incurable and new therapeutic approaches are therefore needed. Deep‐sequencing analysis revealed the presence of BRAF mutations in up to 15% of patients. The clinical experience of BRAF‐targeted therapy in myeloma patients harboring BRAF mutation is...

Celý popis

Podrobná bibliografie
Hlavní autoři: Baptiste Le Calvez, Yannick Le Bris, Guillaume Herbreteau, Bastien Jamet, Céline Bossard, Benoit Tessoulin, Thomas Gastinne, Béatrice Mahé, Viviane Dubruille, Nicolas Blin, Chloé Antier, Olivier Theisen, Françoise Kraeber‐Bodéré, Steven Le Gouill, Marie C. Béné, Philippe Moreau, Cyrille Touzeau
Médium: Článek
Jazyk:English
Vydáno: Wiley 2020-07-01
Edice:eJHaem
Témata:
BRAF
dabrafenib
multiple myeloma
RAS
trametinib
On-line přístup:https://doi.org/10.1002/jha2.8

Internet

https://doi.org/10.1002/jha2.8

Podobné jednotky